Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(7):494-495; doi:10.1093/jnci/djk128
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pritchard, K. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pritchard, K. I.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

EDITORIALS

Adjuvant Therapy for Breast Cancer: We Are Solving the Puzzle, But Pieces Are Still Missing

Kathleen I. Pritchard

Correspondence to: Kathleen I. Pritchard, MD, FRCPC, Clinical Trials & Epidemiology, Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Ave, T2-185, Toronto, ON M4N 3M5, Canada (e-mail: kathy.pritchard@sunnybrook.ca).

The first 10% of the full text of this article appears below.

Two interesting trials from the Adjuvant Breast Cancer (ABC) Trials Collaborative Group (1,2) are reported in this issue of the Journal. Although their interpretation is impeded by the lack of estrogen receptor (ER) measurements in more than 40% of patients, these trials provide important information regarding adjuvant therapy for women with breast cancer.

The ABC Ovarian Ablation or Suppression (OAS) Trial examines women randomly allocated to receive ovarian ablation or suppression compared with no ovarian ablation or suppression, against a background of 5 years of tamoxifen treatment with or without chemotherapy. Among 2144 women who were randomly assigned between 1993 and 2000, there was no evidence of benefit for relapse-free survival (hazard ratio [HR] = 0.95, 95% confidence interval [CI] = 0.81 . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Ovarian Ablation or Suppression in Premenopausal Early Breast Cancer: Results From the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial
The Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst 2007 99: 516-525. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 493. [Extract] [Full Text] [PDF]

Press Release: Combining Therapies Can Improve Survival for Early-Stage Breast Cancer Patients
Liz Savage
J Natl Cancer Inst 2007 99: 493. [Extract] [Full Text]